Amphotericin B- and voriconazole-echinocandin combinations against Aspergillus spp.: Effect of serum on inhibitory and fungicidal interactions

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 10, 2013, Pages 4656-4663

  Elefanti, Antigoni ^a   Mouton, Johan W ^b   Verweij, Paul E ^b   Tsakris, Athanassios ^c   Zerva, Loukia ^a   Meletiadis, Joseph ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; MICAFUNGIN; VORICONAZOLE;

ARTICLE; ASPERGILLUS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS TERREUS; BROTH DILUTION; CONTROLLED STUDY; DRUG INHIBITION; DRUG POTENTIATION; FUNGICIDAL ACTIVITY; FUNGUS ISOLATION; GROWTH INHIBITION; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; SPECIES DIFFERENCE;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLUS; DRUG INTERACTIONS; ECHINOCANDINS; FUNGAL PROTEINS; HUMANS; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; SERUM; TRIAZOLES;

EID: 84884218495     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00597-13     Document Type: Article

References (64)

1. Maschmeyer G, Haas A, Cornely OA. 2007. Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients. Drugs 67:1567-1601.
2. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF. 2008. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46:327-360.
3. Mikulska M, Viscoli C. 2011. Current role of echinocandins in the management of invasive aspergillosis. Curr. Infect. Dis. Rep. 13:517-527.
4. Garbati MA, Alasmari FA, Al-Tannir MA, Tleyjeh IM. 2012. The role of combination antifungal therapy in the treatment of invasive aspergillosis: a systematic review. Int. J. Infect. Dis. 16(2):e76-e81. doi:10.1016/j.ijid .2011.10.004.
5. Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. 2004. Combination antifungal therapy for invasive aspergillosis. Clin. Infect. Dis. 39:797-802.
6. Singh N, Pursell KJ. 2008. Combination therapeutic approaches for the management of invasive aspergillosis in organ transplant recipients. Mycoses 51:99-108.
7. Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. 2007. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin. Infect. Dis. 44:531-540.
8. Marr K, Schlamm H, Rottinghaus ST, Jagannatha S, Bow EJ, Wingard JR, Pappas P, Herbrecht P, Walsh TJ, Maertens J. 2012. A randomised, double-blind study of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis, abstr LB2812. Abstr. 22nd Eur. Congr. Clin. Microbiol. Infect. Dis, London, United Kingdom.
9. Caillot D, Thiebaut A, Herbrecht R, de Botton S, Pigneux A, Bernard F, Larche J, Monchecourt F, Alfandari S, Mahi L. 2007. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). Cancer 110:2740-2746.
10. Nishi I, Sunada A, Toyokawa M, Asari S, Iwatani Y. 2011. Evaluation of amphotericin B and micafungin combination against clinical isolates of Aspergillus species. J. Chemother. 23:102-106.
11. Spreghini E, Orlando F, Santinelli A, Pisa E, Loretelli C, Manso E, Milici ME, Scalise G, Barchiesi F. 2009. Anidulafungin in combination with amphotericin B against Aspergillus fumigatus. Antimicrob. Agents Chemother. 53:4035-4039.
12. Jeans AR, Howard SJ, Al-Nakeeb Z, Goodwin J, Gregson L, Warn PA, Hope WW. 2012. Combination of voriconazole and anidulafungin for treatment of triazole-resistant Aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 56: 5180-5185.
13. Krishnan-Natesan S, Wu W, Chandrasekar PH. 2012. In vitro efficacy of the combination of voriconazole and anidulafungin against voriconazoleresistant cyp51A mutants of Aspergillus fumigatus. Diagn. Microbiol. Infect. Dis. 73:135-137.
14. Lewis RE, Kontoyiannis DP. 2005. Micafungin in combination with voriconazole in Aspergillus species: a pharmacodynamic approach for detection of combined antifungal activity in vitro. J. Antimicrob. Chemother. 56:887-892.
15. Perea S, Gonzalez G, Fothergill AW, Kirkpatrick WR, Rinaldi MG, Patterson TF. 2002. In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrob. Agents Chemother. 46:3039-3041.
16. Calvo E, Pastor FJ, Salas V, Mayayo E, Guarro J. 2012. Combined therapy of voriconazole and anidulafungin in murine infections by Aspergillus flavus. Mycopathologia 173:251-257.
17. Kirkpatrick WR, Perea S, Coco BJ, Patterson TF. 2002. Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. Antimicrob. Agents Chemother. 46:2564-2568.
18. MacCallum DM, Whyte JA, Odds FC. 2005. Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis. Antimicrob. Agents Chemother. 49:3697-3701.
19. van de Sande WW, Mathot RA, ten Kate MT, van Vianen W, Tavakol M, Rijnders BJ, Bakker-Woudenberg IA. 2009. Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin. Antimicrob. Agents Chemother. 53:2005-2013.
20. Chandrasekar PH, Cutright JL, Manavathu EK. 2004. Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive pulmonary aspergillosis. Clin. Microbiol. Infect. 10:925-928.
21. Clemons KV, Espiritu M, Parmar R, Stevens DA. 2005. Comparative efficacies of conventional amphotericin B, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis. Antimicrob. Agents Chemother. 49:4867-4875.
22. Graybill JR, Bocanegra R, Gonzalez GM, Najvar LK. 2003. Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B and micafungin. J. Antimicrob. Chemother. 52:656-662.
23. Nagasaki Y, Eriguchi Y, Uchida Y, Miyake N, Maehara Y, Kadowaki M, Harada M, Akashi K, Shimono N. 2009. Combination therapy with micafungin and amphotericin B for invasive pulmonary aspergillosis in an immunocompromised mouse model. J. Antimicrob. Chemother. 64:379-382.
24. Sionov E, Mendlovic S, Segal E. 2006. Efficacy of amphotericin B or amphotericin B-intralipid in combination with caspofungin against experimental aspergillosis. J. Infect. 53:131-139.
25. Sivak O, Bartlett K, Risovic V, Choo E, Marra F, Batty DS, Jr, Wasan KM. 2004. Assessing the antifungal activity and toxicity profile of amphotericin B lipid complex (ABLC; Abelcet) in combination with caspofungin in experimental systemic aspergillosis. J. Pharm. Sci. 93:1382-1389.
26. EUCAST. 2008. Technical note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds. Clin. Microbiol. Infect. 14:982-984.
27. CLSI. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard, 2nd ed, M38-A2. CLSI, Wayne, PA.
28. Andes D. 2006. Pharmacokinetics and pharmacodynamics of antifungals. Infect. Dis. Clin. North Am. 20:679-697.
29. Drobot GR, Karlowsky JA, Hoban DJ, Zhanel GG. 1996. Antibiotic activity in microbiological media versus that in human urine: comparison of ampicillin, ciprofloxacin, and trimethoprim-sulfamethoxazole. Antimicrob. Agents Chemother. 40:237-240.
30. Zhanel GG, Kirkpatrick ID, Hoban DJ, Kabani AM, Karlowsky JA. 1998. Influence of human serum on pharmacodynamic properties of an investigational glycopeptide, LY333328, and comparator agents against Staphylococcus aureus. Antimicrob. Agents Chemother. 42:2427-2430.
31. Craig WA, Ebert SC. 1989. Protein binding and its significance in antibacterial therapy. Infect. Dis. Clin. North Am. 3:407-414.
32. Ishikawa J, Maeda T, Matsumura I, Yasumi M, Ujiie H, Masaie H, Nakazawa T, Mochizuki N, Kishino S, Kanakura Y. 2009. Antifungal activity of micafungin in serum. Antimicrob. Agents Chemother. 53: 4559-4562.
33. Maki K, Matsumoto S, Watabe E, Iguchi Y, Tomishima M, Ohki H, Yamada A, Ikeda F, Tawara S, Mutoh S. 2008. Use of a serum-based antifungal susceptibility assay to predict the in vivo efficacy of novel echinocandin compounds. Microbiol. Immunol. 52:383-391.
34. Paderu P, Garcia-Effron G, Balashov S, Delmas G, Park S, Perlin DS. 2007. Serum differentially alters the antifungal properties of echinocandin drugs. Antimicrob. Agents Chemother. 51:2253-2256.
35. Zhanel GG, Saunders DG, Hoban DJ, Karlowsky JA. 2001. Influence of human serum on antifungal pharmacodynamics with Candida albicans. Antimicrob. Agents Chemother. 45:2018-2022.
36. Chiller T, Farrokhshad K, Brummer E, Stevens DA. 2000. Influence of human sera on the in vitro activity of the echinocandin caspofungin (MK-0991) against Aspergillus fumigatus. Antimicrob. Agents Chemother. 44: 3302-3305.
37. Elefanti A, Mouton JW, Krompa K, Al-Saigh R, Verweij PE, Zerva L, Meletiadis J. 2013. Inhibitory and fungicidal pharmacodynamic effects of antifungal drugs against Aspergillus species in the presence of serum. Antimicrob. Agents Chemother. 57:1625-1631.
38. Gifford AH, Klippenstein JR, Moore MM. 2002. Serum stimulates growth of and proteinase secretion by Aspergillus fumigatus. Infect. Immun. 70:19-26.
39. Rodrigues AG, Araujo R, Pina-Vaz C. 2005. Human albumin promotes germination, hyphal growth and antifungal resistance by Aspergillus fumigatus. Med. Mycol. 43:711-717.
40. Kauffman CA, Carver PL. 2008. Update on echinocandin antifungals. Semin. Respir. Crit. Care Med. 29:211-219.
41. Bellmann R. 2007. Clinical pharmacokinetics of systemically administered antimycotics. Curr. Clin. Pharmacol. 2:37-58.
42. Antachopoulos C, Meletiadis J, Sein T, Roilides E, Walsh TJ. 2008. Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. Antimicrob. Agents Chemother. 52:321-328.
43. Meletiadis J, Antachopoulos C, Stergiopoulou T, Pournaras S, Roilides E, Walsh TJ. 2007. Differential fungicidal activities of amphotericin B and voriconazole against Aspergillus species determined by microbroth methodology. Antimicrob. Agents Chemother. 51:3329-3337.
44. Meletiadis J, Mouton JW, Meis JF, Bouman BA, Donnelly JP, Verweij PE. 2001. Colorimetric assay for antifungal susceptibility testing of Aspergillus species. J. Clin. Microbiol. 39:3402-3408.
45. Antachopoulos C, Meletiadis J, Sein T, Roilides E, Walsh TJ. 2007. Concentration-dependent effects of caspofungin on the metabolic activity of Aspergillus species. Antimicrob. Agents Chemother. 51:881-887.
46. Meletiadis J, Petraitis V, Petraitiene R, Lin P, Stergiopoulou T, Kelaher AM, Sein T, Schaufele RL, Bacher J, Walsh TJ. 2006. Triazole-polyene antagonism in experimental invasive pulmonary aspergillosis: in vitro and in vivo correlation. J. Infect. Dis. 194:1008-1018.
47. Tallarida RJ. 2002. The interaction index: a measure of drug synergism. Pain 98:163-168.
48. Meletiadis J, Pournaras S, Roilides E, Walsh TJ. 2010. Defining fractional inhibitory concentration index cutoffs for additive interactions based on self-drug additive combinations, Monte Carlo simulation analysis, and in vitro-in vivo correlation data for antifungal drug combinations against Aspergillus fumigatus. Antimicrob. Agents Chemother. 54: 602-609.
49. Arikan S, Lozano-Chiu M, Paetznick V, Rex JH. 2002. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob. Agents Chemother. 46:245-247.
50. Cuenca-Estrella M, Gomez-Lopez A, Garcia-Effron G, Alcazar-Fuoli L, Mellado E, Buitrago MJ, Rodriguez-Tudela JL. 2005. Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus. Antimicrob. Agents Chemother. 49:1232-1235.
51. Dannaoui E, Lortholary O, Dromer F. 2004. In vitro evaluation of double and triple combinations of antifungal drugs against Aspergillus fumigatus and Aspergillus terreus. Antimicrob. Agents Chemother. 48: 970-978.
52. Planche V, Ducroz S, Alanio A, Bougnoux ME, Lortholary O, Dannaoui E. 2012. In vitro combination of anidulafungin and voriconazole against intrinsically azole-susceptible and-resistant Aspergillus spp. Antimicrob. Agents Chemother. 56:4500-4503.
53. Odds FC. 2003. Synergy, antagonism, and what the chequerboard puts between them. J. Antimicrob. Chemother. 52:1. doi:10.1093/jac/dkg301.
54. Meletiadis J, Verweij PE, TeDorsthorst DT, Meis JF, Mouton JW. 2005. Assessing in vitro combinations of antifungal drugs against yeasts and filamentous fungi: comparison of different drug interaction models. Med. Mycol. 43:133-152.
55. Meletiadis J, Elefanti A, Zerva L, Verweij PE, Mouton JW. 2012. In vitro interactions with fractional inhibitory concentration (FIC) indices between 0.5 and 4 are in vivo important. A need to revisit FIC index cutoffs. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA. http://www.icaac.org/.
56. O'Shaughnessy EM, Meletiadis J, Stergiopoulou T, Demchok JP, Walsh TJ. 2006. Antifungal interactions within the triple combination of amphotericin B, caspofungin and voriconazole against Aspergillus species. J. Antimicrob. Chemother. 58:1168-1176.
57. Berenbaum MC. 1989. What is synergy? Pharmacol. Rev. 41:93-141.
58. Shalit I, Shadkchan Y, Samra Z, Osherov N. 2003. In vitro synergy of caspofungin and itraconazole against Aspergillus spp.: MIC versus minimal effective concentration end points. Antimicrob. Agents Chemother. 47:1416-1418.
59. Shields RK, Nguyen MH, Du C, Press E, Cheng S, Clancy CJ. 2011. Paradoxical effect of caspofungin against Candida bloodstream isolates is mediated by multiple pathways but eliminated in human serum. Antimicrob. Agents Chemother. 55:2641-2647.
60. Steinbach WJ, Singh N, Miller JL, Benjamin DK, Jr, Schell WA, Heitman J, Perfect JR. 2004. In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and nontransplant patients. Antimicrob. Agents Chemother. 48: 4922-4925.
61. Olson JA, George A, Constable D, Smith P, Proffitt RT, Adler-Moore JP. 2010. Liposomal amphotericin B and echinocandins as monotherapy or sequential or concomitant therapy in murine disseminated and pulmonary Aspergillus fumigatus infections. Antimicrob. Agents Chemother. 54:3884-3894.
62. Wasan KM, Sivak O, Rosland M, Risovic V, Bartlett K. 2007. Assessing the antifungal activity, pharmacokinetics, and tissue distribution of amphotericin B following the administration of Abelcet and AmBisome in combination with caspofungin to rats infected with Aspergillus fumigatus. J. Pharm. Sci. 96:1737-1747.
63. Seyedmousavi S, Bruggemann RJ, Melchers WJ, Rijs AJ, Verweij PE, Mouton JW. 2013. Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis. J. Antimicrob. Chemother. 68:385-393.
64. Olson JA, Schwartz J, Hahka D, George A, Proffitt RT, Adler-Moore JP. 2012. Differences in efficacy and cytokine profiles following echinocandin or liposomal amphotericin B monotherapy or combination therapy for murine pulmonary or systemic Aspergillus flavus infections. Antimicrob. Agents Chemother. 56:218-230.